bluebird bio announced that it has commenced an underwritten public offering of $150M of shares of its common stock. All shares in the offering are to be sold by bluebird. bluebird intends to use the net proceeds of the offering (i) to support commercialization and manufacturing for its three approved gene therapies, ZYNTEGLO, SKYSONA and LYFGENIA; and (ii) to fund working capital and other general corporate purposes. Goldman Sachs and J.P. Morgan Securities are acting as joint book running managers for the offering. Raymond James is acting as co-manager for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BLUE:
- Short Report: Rebound in Guess and GroupOn shares driving short-covering
- Bluebird Bio price target lowered by $3 at Wells Fargo, here’s why
- Bluebird Bio price target lowered to $5 from $8 at Wells Fargo
- Bluebird in deal with group representing 100M covered lives, after FDA approval
- Bluebird Bio pricing and label concerns are overdone, says Baird
